LIGAND PHARMACEUTICALS INCORPORATED
(LGND)Financial Statements · SEC EDGAR XBRL
Net Income
$124.5M
+3186.6%
EPS
$6.13
+2886.4%
Op. Income
$41.0M
+281.4%
FCF
$48.9M
-48.6%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)